← Back to guidelines
Infectious Disease40 papers

Left ventricular failure with sepsis

Last edited: 4/10/2026

Overview

Left ventricular failure in the context of sepsis refers to impaired cardiac function, specifically the heart's ability to pump blood effectively, occurring as a complication of severe infection and systemic inflammation. This can manifest as reduced cardiac output and inadequate tissue perfusion.

Diagnosis

Management

  • Ultra-short-acting beta-blockers (esmolol or landiolol) did not significantly improve mortality in patients with sepsis and persistent tachycardia 1.
  • Adjunctive vasopressors added to norepinephrine may reduce short-term mortality in adults with septic shock (low certainty evidence) 2.
  • Each hour of delay in antibiotic administration after the first hour increases in-hospital mortality in patients with sepsis or septic shock 3.
  • Early versus late norepinephrine administration showed no significant difference in overall mortality in septic shock patients in RCTs, but may be beneficial in specific scenarios without restrictive fluid strategies 4.
  • Restrictive fluid resuscitation did not significantly reduce mortality in patients with sepsis compared to usual care 5.
  • Limited fluid resuscitation may be beneficial for septic shock patients, reducing mortality, multiple organ dysfunction syndrome, ARDS, and DIC 7.
  • Special Populations

    Key Recommendations

  • Administer antibiotics as soon as possible in patients with sepsis or septic shock, as each hour of delay after the first hour increases in-hospital mortality 3. (Evidence: Moderate)
  • Consider adjunctive vasopressors in adults with septic shock, as they may reduce short-term mortality 2. (Evidence: Weak)
  • Limited fluid resuscitation may be beneficial in septic shock patients, potentially reducing mortality and organ dysfunction 7. (Evidence: Moderate)
  • Ultra-short-acting beta-blockers (esmolol or landiolol) are not recommended to improve mortality in patients with sepsis and persistent tachycardia 1. (Evidence: Moderate)
  • References

    1 Sato R, Messina S, Hasegawa D, Santonocito C, Scimonello G, Sanfilippo G et al.. Mortality in Patients With Sepsis Treated With Esmolol or Landiolol: A Systematic Review and Meta-Analysis of Randomized Controlled Trials With Trial Sequential Analysis. Chest 2025. link 2 Bauer SR, Wieruszewski PM, Bissell Turpin BD, Dugar S, Sacha GL, Sato R et al.. ADJUNCTIVE VASOPRESSORS AND SHORT-TERM MORTALITY IN ADULTS WITH SEPTIC SHOCK: A SYSTEMATIC REVIEW AND META-ANALYSIS. Shock (Augusta, Ga.) 2025. link 3 Tang F, Yuan H, Li X, Qiao L. Effect of delayed antibiotic use on mortality outcomes in patients with sepsis or septic shock: A systematic review and meta-analysis. International immunopharmacology 2024. link 4 Ahn C, Yu G, Shin TG, Cho Y, Park S, Suh GY. Comparison of Early and Late Norepinephrine Administration in Patients With Septic Shock: A Systematic Review and Meta-Analysis. Chest 2024. link 5 Reynolds PM, Stefanos S, MacLaren R. Restrictive resuscitation in patients with sepsis and mortality: A systematic review and meta-analysis with trial sequential analysis. Pharmacotherapy 2023. link 6 Liu YC, Yao Y, Yu MM, Gao YL, Qi AL, Jiang TY et al.. Frequency and mortality of sepsis and septic shock in China: a systematic review and meta-analysis. BMC infectious diseases 2022. link 7 Jiang S, Wu M, Lu X, Zhong Y, Kang X, Song Y et al.. Is restrictive fluid resuscitation beneficial not only for hemorrhagic shock but also for septic shock?: A meta-analysis. Medicine 2021. link

    Original source

    1. [1]
    2. [2]
      ADJUNCTIVE VASOPRESSORS AND SHORT-TERM MORTALITY IN ADULTS WITH SEPTIC SHOCK: A SYSTEMATIC REVIEW AND META-ANALYSIS.Bauer SR, Wieruszewski PM, Bissell Turpin BD, Dugar S, Sacha GL, Sato R et al. Shock (Augusta, Ga.) (2025)
    3. [3]
    4. [4]
    5. [5]
    6. [6]
      Frequency and mortality of sepsis and septic shock in China: a systematic review and meta-analysis.Liu YC, Yao Y, Yu MM, Gao YL, Qi AL, Jiang TY et al. BMC infectious diseases (2022)
    7. [7]

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG